Back to search results

Evaluating Pharmacogenetic Testing in Cancer Patients

This study is looking at how a special genetic test, called "Global Diversity Array with Enhanced PGx" (pharmacogenomic or PGx testing), can help doctors decide on the best cancer treatments and supportive care medications for you. This test looks at your genes to see how your body might react to certain medicines. You might be able to join if you are an adult (18 or older) with cancer, including gastrointestinal cancer, and are already eligible for a standard DPYD gene test because you are receiving or will receive a fluoropyrimidine-based chemotherapy. The main goal is to see how many useful results the PGx test provides that can guide your treatment. The current status of this study is unclear.

Study design
This is a Phase 2 study that is not randomized, meaning participants are not assigned to groups by chance. It plans to include 120 adult participants.
What's involved
You will have a pharmacogenomic test, and the results will be added to your medical record. You will be followed for about 6 months to collect information on your prescriptions and any actions taken based on the test results.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for approximately 6 months after the test results are available.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06489041

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
Wake Forest University Health Sciences
~120 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of potentially actionable results based on pharmacogenomic (PGx) test
Measured over Baseline

Conditions

Cancer
Gastrointestinal Cancer

Explore related trials

Malignant Digestive System NeoplasmMalignant NeoplasmDPYD Gene

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Jai Patel, PharmD · PRINCIPAL_INVESTIGATOR · Atrium Health Levine Cancer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent and HIPAA authorization for release of personal health information.
Age ≥ 18 years at the time of consent.
Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.

What this trial measures

  • Number of potentially actionable results based on pharmacogenomic (PGx) testBaseline

    A potentially actionable result refers to any genotype or phenotype that is associated with specific drug-gene interactions from the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines or the FDA's Table of Pharmacogenetic Associations. The number of potentially actionable results is a count variable that represents the total occurrences of such genotypes or phenotypes identified in a participant.